ClinicalTrials.gg
Active, not recruitingNCT05905133Updated Dec 11, 2023

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

A Phase 2 interventional study of CBP-201 in Atopic Dermatitis, sponsored by Connect Biopharm LLC. Active, not recruiting at 38 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Connect Biopharm LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
46th of 190
360 · median 164
Started
2023
with 38 others
Phase 2
58 of 206
16 open now
Primary completion
2024-06
later than 6 of 81 live
Registered
72nd of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 46th largest by enrollment of the 190 interventional ones that give a count, is one of 39 that started in 2023, is one of 58 in phase 2, reaches primary completion later than 6 of the 81 other live ones, and was the 72nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This study is a single-arm, open-label, multi-center clinical study designed to assess the safety and efficacy of CBP-201 in eligible subjects with moderate to severe Atopic Dermatitis.

Read the detailed description

The study includes a screening period, a treatment period and a follow-up period.

The subjects will receive a subcutaneous injection of CBP-201 600 mg (4 mL in total, 2 injections of 2 mL each in different sites) on Day1, begin to receive a subcutaneous injection of CBP-201 300 mg (2 mL) from Week2, and receive CBP-201 300 mg (2 mL) every 2 weeks thereafter until Week10.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 ≤ age ≤ 75 years at the screening visit, male or female.
  2. Diagnosed with atopic dermatitis (according to the American Academy of Dermatology's Guidelines of care for the management of atopic dermatitis, 2014[1]) at the time of screening, and meeting all the 4 criteria below:

    1. Suffering from the disease for more than 1 year at the time of screening;
    2. At the screening and baseline visit, IGA score ≥ 3 (according to the validated Investigator Global Assessment for Atopic Dermatitis [vIGA-AD™] scale);
    3. EASI score ≥ 12;
    4. Percentage of total BSA affected by AD ≥ 10%.
  3. Female subjects of (FCBP) and male subjects who have not undergone vasectomy must agree to take highly effective measures during the entire study period (from the signing of forms (ICFs) to the 8-week follow-up period after discontinuation of study drug). women (determined by testing follicle stimulating hormone [FSH]; defined as the women who have had amenorrhea for at least 12 consecutive months without using drugs known to cause amenorrhea, and have a recorded FSH level greater than 40 mIU/mL or in the postmenopausal range) and women with a record of surgical sterilization (i.e., tubal ligation or hysterectomy or bilateral oophorectomy) before the screening visit can be considered infertile.

    Highly effective contraceptive measures include:

    i. Abstinence (acceptable only if it is part of the subject's routine lifestyle); ii. Hormones (oral, patch, ring, injection, implant) combined with male condoms. This measure must be used at least 30 days before the first study drug administration. Otherwise, another acceptable method of contraception must be used; iii. Intrauterine device (IUD) combined with male condoms.

  4. Subjects are willing and able to comply with study visits and related procedures.
  5. Subjects have the ability to learn the study requirements and process, and voluntarily take part in the clinical trial and sign an ICF.

Exclusion criteria

Exclusion Criteria:

  1. Received prior treatment with anti-interleukin-4 receptor α (IL-4Rα)/anti-interleukin-13 (IL-13) antibodies with a poor response (including treatment failure or development of unacceptable treatment-related adverse reactions).
  2. Have received any of the following topical treatments within 2 weeks before D1 visit: phosphodiesterase-4 (PDE-4) inhibitors, Janus kinase (JAK) inhibitors, or aromatic hydrocarbon receptor agonists.
  3. Have received systemic treatment with (except for corticosteroid inhalers and nasal sprays) or other /immunomodulatory agents (including but not limited to cyclosporine, mycophenolate mofetil, azathioprine, methotrexate, JAK inhibitors, and various biological agents) within 2 weeks before D1 visit or 5 drug half-lives (if known), whichever is longer.
  4. Have received treatment with immune cell depletion agents (e.g., rituximab) within 6 months before D1 visit.
  5. Have received any drug/treatment within 4 weeks before D1 visit or 5 drug half-lives (if known), whichever is longer.
  6. Other skin complications in addition to AD that may interfere with the study assessments.
  7. There is a known or suspected history of immunosuppression/immunodeficiency within 6 months before D1 visit (including but not limited to a history of invasive opportunistic infections, such as aspergillosis, coccidiosis, histoplasmosis, acquired immunodeficiency syndrome (AIDS), listeriosis, or Pneumocystis, even if the infection has subsided), or there is an abnormally frequently recurrent or persistent infection.
  8. Received systemic treatment with anti-infective drugs (including but not limited to antibiotics, antiviral drugs, antiparasitic drugs, antiprotozoal drugs, or antifungal drugs) due to acute or chronic infection within 1 week before D1 visit (after the infection subsides, the subjects can be rescreened).
  9. History of malignant tumor within 5 years before D1 visit (except for completely cured cervical carcinoma in situ or non- cutaneous squamous cell carcinoma or basal cell carcinoma).
  10. History of parasite infection within 6 months before D1 visit.
  11. Positive for surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and HBV-DNA, or positive for antibody and HCV ribonucleic acid (RNA) polymerase chain reaction, or serologically positive for (HIV) at the screening visit.
  12. Subjects with active tuberculosis, latent tuberculosis, or a history of nontuberculous mycobacterial infection at screening;

    Note:

    • Unless there is a clear medical record proving that the subject has received adequate treatment and is currently able to start receiving biological treatment (based on the medical judgment of the investigator and/or infectious disease specialist);
    • If needed, an interferon gamma release assay may be used to assist diagnosis of suspected tuberculosis.
  13. Any of the following laboratory test abnormalities at the screening visit:

    1. or alanine aminotransferase > 2 times the (ULN);
    2. Total > 1.5 × ULN;
    3. Serum creatinine > 1.2 × ULN;
    4. White blood cell count \< 3.0 × 109/L or ≥ 14 × 109/L; Note: If the subjects have the above laboratory test abnormalities at screening, after being assessed as necessary by the investigator, they are allowed to receive a retest on another day within 28 days of the screening period, and those qualified for the retest are permitted to be enrolled (it is forbidden to conduct drug intervention for those laboratory test abnormalities before retest).
  14. History of to L-histidine, trehalose or Tween (polysorbate) 80, or systemic hypersensitivity reactions to any biological agents (except local injection site reactions).
  15. History of alcohol or drug abuse within 2 years before D1 visit.
  16. Have been vaccinated with (attenuated) within 8 weeks before D1 visit, or planning to be vaccinated during the study period.
  17. Planning to undergo major surgical operations during the study period.
  18. Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
  19. Any other conditions (e.g., those may increase the risks of the subjects, or may affect/interfere with the assessment of the study) that the investigator deems unsuitable for participation in this study, including but not limited to: prior or current physical or mental illness, physical examination results, vital signs, or safety laboratory test abnormalities at screening. The specific reasons for subjects excluded due to this criterion will be indicated in the study documents (including medical records and electronic case report form (eCRF)).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    CBP-201

    The subjects will receive CBP-201 600 mg (4 mL in total, 2 injections of 2 mL each in different sites) on Day1, begin to receive a subcutaneous injection of CBP-201 300 mg (2 mL) from Week2, and receive CBP-201 300 mg (2 mL) every 2 weeks thereafter until Week10.

    Drug: CBP-201

Interventions

  • subcutaneous injection

    Also known as: CBP-201 injection

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    cases/person-years

    Time frame: From Day 1 study drug first administrated to Week 20

Secondary outcomes

  1. Incidence of treatment-related treatment-emergent adverse events (TEAEs)

    cases/person-years

    Time frame: From Day 1 study drug first administrated to Week 20

  2. Incidence of serious adverse events (SAEs)

    cases/person-years

    Time frame: From Day 1 study drug first administrated to Week 20

  3. Incidence of treatment-related serious adverse events (SAEs)

    cases/person-years

    Time frame: From Day 1 study drug first administrated to Week 20

  4. Incidence of adverse events of special interest (AESIs)

    cases/person-years

    Time frame: From Day 1 study drug first administrated to Week 20

  5. Abnormal changes in vital signs

    Vital signs (VS): including body temperature, respiration rate, blood pressure, and heart rate.

    Time frame: Pre-dose, Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141

  6. Abnormal changes in physical examination

    Physical examination included are as follows: general appearance, skin, ears/nose/throat, head and neck, cardiovascular system, respiratory system, abdomen, limbs, lymph nodes, musculoskeletal and nervous systems.

    Time frame: Pre-dose, Day85, Day141

  7. Abnormal changes in laboratory tests: Hematology

    White blood cell count, Hemoglobin, Hematocrit, Red blood cell count, Platelet count, Neutrophil percentage, Lymphocyte percentage, Monocyte percentage, Basophil percentage, Eosinophil percentage, Absolute neutrophil count, Absolute lymphocyte count, Absolute monocyte count, Absolute eosinophil count, Absolute basophil count

    Time frame: Pre-dose, Day1, Day15, Day29, Day57, Day85, Day141

  8. Abnormal changes in laboratory tests: Blood biochemistry

    Sodium, Potassium, Calcium, Chlorine, Serum urea/urea nitrogen, Creatinine, Glucose, Total protein, Albumin, Total bilirubin, Alanine aminotransaminase, Aspartate aminotransferase, γ-glutamyltransferase, Alkaline phosphatase, Lactate dehydrogenase, Creatine phosphokinase, Total cholesterol, Low-density lipoprotein, High-density lipoprotein

    Time frame: Pre-dose, Day1, Day15, Day29, Day57, Day85, Day141

  9. Abnormal changes in laboratory tests: Urinalysis

    Urine bilirubin, Urine red blood cells, Urine white blood cells, Urine glucose, Urine ketone, Urine nitrite, Urine pH, Urine protein, Urine specific gravity, Urobilinogen, Microscopic examination (if necessary)

    Time frame: Pre-dose, Day1, Day15, Day29, Day57, Day85, Day141

  10. Abnormal changes in electrocardiogram (ECG) parameters

    ECG variables include ventricular heart rate and PR, QRS, QT, and QTcF intervals.

    Time frame: Pre-dose, Day1, Day141

  11. Proportion of subjects achieving greater than or equal to 75% improvement in Eczema Area and Severity Index (EASI-75)

    The Eczema Area and Severity Index (EASI) scale quantifies the severity and extent of Atopic Dermatitis, as well as the severity of erythema, infiltration, excoriation, and lichenification of the four anatomical regions-head and neck, trunk, upper extremities, and lower extremities.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day113, Day141

  12. Proportion of subjects whose Investigator Global Assessment (IGA) score is 0-1 and decreased by ≥ 2 points from baseline

    The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day113, Day141

  13. Proportion of subjects achieving greater than or equal to 50% improvement in Eczema Area and Severity Index (EASI-50)

    The Eczema Area and Severity Index (EASI) scale quantifies the severity and extent of Atopic Dermatitis, as well as the severity of erythema, infiltration, excoriation, and lichenification of the four anatomical regions-head and neck, trunk, upper extremities, and lower extremities.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day113, Day141

  14. Proportion of subjects achieving greater than or equal to 90% improvement in Eczema Area and Severity Index (EASI-90)

    The Eczema Area and Severity Index (EASI) scale quantifies the severity and extent of Atopic Dermatitis, as well as the severity of erythema, infiltration, excoriation, and lichenification of the four anatomical regions-head and neck, trunk, upper extremities, and lower extremities.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day113, Day141

  15. Proportion of subjects achieving 100% improvement in Eczema Area and Severity Index (EASI-100)

    The Eczema Area and Severity Index (EASI) scale quantifies the severity and extent of Atopic Dermatitis, as well as the severity of erythema, infiltration, excoriation, and lichenification of the four anatomical regions-head and neck, trunk, upper extremities, and lower extremities.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day113, Day141

  16. Proportion of subjects whose IGA score is decreased by ≥ 2 points from baseline

    The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day113, Day141

  17. Proportion of subjects with IGA score ≤ 2 (equivalent to reaching a low disease activity state)

    The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day113, Day141

  18. Proportion of subjects whose weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) is decreased by ≥ 3 points from baseline

    Peak Pruritus Numerical Rating Scale (PP-NRS) is a single self-reported item designed to measure the peak pruritus or the "worst" pruritus in the previous 24 hours.

    Time frame: Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141

  19. Proportion of subjects whose weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) is decreased by ≥ 4 points from baseline

    Peak Pruritus Numerical Rating Scale (PP-NRS) is a single self-reported item designed to measure the peak pruritus or the "worst" pruritus in the previous 24 hours.

    Time frame: Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141

  20. Change and percentage change in the EASI score from baseline

    The Eczema Area and Severity Index (EASI) scale quantifies the severity and extent of Atopic Dermatitis, as well as the severity of erythema, infiltration, excoriation, and lichenification of the four anatomical regions-head and neck, trunk, upper extremities, and lower extremities.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day113, Day141

  21. Change and percentage change in the weekly average PP-NRS from baseline

    Peak Pruritus Numerical Rating Scale (PP-NRS) is a single self-reported item designed to measure the peak pruritus or the "worst" pruritus in the previous 24 hours.

    Time frame: Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141

  22. Change and percentage change in the body surface area (BSA) affected by Atopic Dermatitis from baseline

    The "Rule of Nines" is used to estimate the maximum percentage of Atopic Dermatitis-affected body surface area (BSA): head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\].

    Time frame: Day1, Day15, Day29, Day57, Day85, Day113, Day141

  23. Change and percentage change in the Dermatology Life Quality Index (DLQI) score from baseline

    Dermatology Life Quality Index (DLQI) is a questionnaire containing 10 items to assess the impact of Atopic Dermatitis on quality of life (QOL) in the past week, and the scores range from 0 (no disease) to 30 (severe disease); the higher the score, the worse the quality of life.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day113, Day141

  24. Proportion of subjects receiving concomitant medications for the treatment of the disease under study (Atopic Dermatitis)

    except emollients; the proportion will be summarized separately by all concomitant medications and the ATC2 codes for concomitant medications

    Time frame: from Day1 to Week12

  25. Proportion of subjects receiving concomitant medications for the treatment of the disease under study (Atopic Dermatitis) prohibited by the protocol

    (except emollients; the proportion will be summarized separately by all concomitant medications, local therapy, systemic treatment, and the ATC2 codes for concomitant medications)

    Time frame: from Day1 to Week12

  26. Proportion of subjects receiving topical corticosteroids (TCS) for the treatment of the disease under study (Atopic Dermatitis)

    If topical corticosteroids (TCS) is considered necessary by the investigator.

    Time frame: from Day1 to Week12

  27. Duration of TCS use for the treatment of the disease under study (Atopic Dermatitis)

    days/person-years

    Time frame: from Day1 to Week12

  28. Percentage of subjects positive for anti-drug antibody (ADA) and ADA titer range

    Descriptive statistics will be used to summarize the baseline values of related measurements (ADA, NAb) and the changes from baseline to each visit.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day141

  29. Percentage of subjects positive for neutralizing antibody (NAb) in subjects positive for ADA

    Descriptive statistics will be used to summarize the baseline values of related measurements (ADA, NAb) and the changes from baseline to each visit.

    Time frame: Day1, Day15, Day29, Day57, Day85, Day141

07

Study locations

38 sites
  • Connect Investigative Site 01
    Beijing, Beijing, China
  • Connect Investigative Site 41
    Beijing, Beijing, China
  • Connect Investigative Site 14
    Fuzhou, Fujian, China
  • Connect Investigative Site 25
    Fuzhou, Fujian, China
  • Connect Investigative Site 03
    Guangzhou, Guangdong, China
  • Connect Investigative Site 11
    Guangzhou, Guangdong, China
  • Connect Investigative Site 13
    Guangzhou, Guangdong, China
  • Connect Investigative Site 20
    Guangzhou, Guangdong, China
  • Connect Investigative Site 22
    Shenzhen, Guangdong, China
  • Connect Investigative Site 31
    Nanning, Guangxi, China
  • Connect Investigative Site 16
    Haikou, Hainan, China
  • Connect Investigative Site 17
    Haikou, Hainan, China
  • Connect Investigative Site 19
    Nanyang, Henan, China
  • Connect Investigative Site 27
    Wuhan, Hubei, China
  • Connect Investigative Site 28
    Yichang, Hubei, China
  • Connect Investigative Site 26
    Changsha, Hunan, China
  • Connect Investigative Site 34
    Nanjing, Jiangsu, China
  • Connect Investigative Site 39
    Suzhou, Jiangsu, China
  • Connect Investigative Site 05
    Zhenjiang, Jiangsu, China
  • Connect Investigative Site 29
    Shenyang, Liaoning, China
  • Connect Investigative Site 40
    Jiangxi, Nanchang, China
  • Connect Investigative Site 24
    Baotou, Nei Monggol, China
  • Connect Investigative Site 18
    Yinchuan, Ningxia, China
  • Connect Investigative Site 30
    Dongying, Shandong, China
  • Connect Investigative Site 21
    Jinan, Shandong, China
  • Connect Investigative Site 35
    Jinan, Shandong, China
  • Connect Investigative Site 36
    Shanghai, Shanghai, China
  • Connect Investigative Site 10
    Taiyuan, Shanxi, China
  • Connect Investigative Site 06
    Xi'an, Shanxi, China
  • Connect Investigative Site 15
    Yuncheng, Shanxi, China
  • Connect Investigative Site 23
    Chengdu, Sichuan, China
  • Connect Investigative Site 02
    Tianjin, Tianjin, China
  • Connect Investigative Site 09
    Ürümqi, Xinjiang, China
  • Connect Investigative Site 07
    Hangzhou, Zhejiang, China
  • Connect Investigative Site 08
    Hangzhou, Zhejiang, China
  • Connect Investigative Site 33
    Hangzhou, Zhejiang, China
  • Connect Investigative Site 37
    Hangzhou, Zhejiang, China
  • Connect Investigative Site 32
    Ningbo, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2024, 11 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 11 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jun 15, 2023
StartActual
Jul 15, 2023
Primary completionEst.
Jun 30, 2024
CompletionEst.
Jun 30, 2024
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05905133
Lead sponsor
Connect Biopharm LLC
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Jul 15, 2023
Primary completion
Jun 30, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Dec 11, 2023

Study contacts

Suzhou Connect
study director · Connect Biopharm LLC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-201

Start the discussion